Wedbush maintains Beam Therapeutics at Outperform, raises price target to $30 from $28
Wedbush kept its Outperform rating on Beam Therapeutics and increased its price target to $30 from $28, citing a 13.9% upside from the Nov 3 close. Recent analyst targets for the company range from $28 to $80.
How this was made

The 30-second read
Why it matters
Analyst target upgrades can generate short‑term buying pressure, especially for low‑float biotech stocks.
Market read
A fresh analyst upgrade provides a modest trading signal for BEAM, but overall market impact is limited.
What to watch
Upcoming clinical trial data or regulatory decisions could dominate price action more than analyst targets.
Background
Wedbush maintains an Outperform rating on Beam Therapeutics and lifts its price target by 7.1% to $30.
Ticker impact
Wedbush raised its price target on Beam Therapeutics to $30 from $28, indicating a fresh analyst upgrade.
likely modest upward pressure as investors price in the higher target
Analyst upgrades typically prompt short‑term buying, but the change is modest and the stock is small‑cap.
Market effects
Small‑cap biotech may see slight uplift as analysts adjust expectations.
U.S. biotech sector could experience modest positive sentiment.
Limited to investors tracking Beam Therapeutics and similar biotech names.
Counterpoint
The price target increase is modest; the stock may already be fully priced in, limiting upside.
Key entities
- CompanyBeam Therapeutics
U.S. biotech focused on gene editing.
- Research FirmWedbush
Equity research firm providing the rating and target.
